Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Prazosin Hydrochloride

FDA-approved product (capsule, oral), marketed as Minipress, Minipress Xl, Prazosin Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Prazosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Prazosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Prazosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort

    NCT06629090 · start 2025-12-17

    Registered record
    Registry ID
    NCT06629090
    Conditions
    Magnetic Resonance Imaging; Cerebrovascular Circulation
    Interventions
    MRI; Prazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-17
    Completion
    2027-05
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMagnetic Resonance Imaging; Cerebrovascular Circulation
    InterventionMRI; Prazosin; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine

    NCT06147622 · start 2024-04-23

    Registered record
    Registry ID
    NCT06147622
    Conditions
    Alcohol Use Disorder
    Interventions
    Prazosin + cyproheptadine; KT110
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-04-23
    Completion
    2024-12-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionPrazosin + cyproheptadine; KT110
    PhasePhase 1
    Registry statusCompleted

  • A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin

    NCT06287905 · start 2023-02-01

    Registered record
    Registry ID
    NCT06287905
    Conditions
    Morality
    Interventions
    Prazosin Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-02-01
    Completion
    2024-07-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorality
    InterventionPrazosin Oral Tablet
    PhasePhase 4
    Registry statusUnknown

  • A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

    NCT05189977 · start 2022-09-07

    Registered record
    Registry ID
    NCT05189977
    Conditions
    Post-traumatic Stress Disorder (PTSD)
    Interventions
    Propranolol; Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2022-09-07
    Completion
    2023-08-03
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-traumatic Stress Disorder (PTSD)
    InterventionPropranolol; Prazosin
    PhasePhase 1
    Registry statusTerminated

  • Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin

    NCT05360953 · start 2022-06-17

    Registered record
    Registry ID
    NCT05360953
    Conditions
    Posttraumatic Stress Disorder
    Interventions
    Clonidine; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2022-06-17
    Completion
    2026-07-31
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder
    InterventionClonidine; Doxazosin; Placebo
    PhasePhase 2
    Registry statusSuspended

  • Reducing Cannabis Overuse With Prazosin

    NCT04721353 · start 2020-11-09

    Registered record
    Registry ID
    NCT04721353
    Conditions
    Cannabis Dependence; Posttraumatic Stress Disorder; Cannabis Use Disorder
    Interventions
    Prazosin Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-11-09
    Completion
    2025-06-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Dependence; Posttraumatic Stress Disorder; Cannabis Use Disorder
    InterventionPrazosin Hydrochloride
    PhasePhase 4
    Registry statusCompleted

  • Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)

    NCT04365257 · start 2020-05-13

    Registered record
    Registry ID
    NCT04365257
    Conditions
    COVID-19
    Interventions
    Prazosin; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-05-13
    Completion
    2022-03-31
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionPrazosin; Standard of care
    PhasePhase 2
    Registry statusTerminated

  • Influence of the Autonomic Nervous System in Response to Exercise in Hypertensive Individuals

    NCT04371757 · start 2020-04-30

    Registered record
    Registry ID
    NCT04371757
    Conditions
    Autonomic Nervous System; Hypertension
    Interventions
    α1-adrenergic block; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-04-30
    Completion
    2021-12-23
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Nervous System; Hypertension
    Interventionα1-adrenergic block; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Prazosin for Agitation in Alzheimer's Disease

    NCT03710642 · start 2018-10-23

    Registered record
    Registry ID
    NCT03710642
    Conditions
    Alzheimer's Disease; Disruptive Behavior
    Interventions
    Prazosin; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-10-23
    Completion
    2022-01-05
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Disruptive Behavior
    InterventionPrazosin; Placebo oral capsule
    PhasePhase 2
    Registry statusCompleted

  • A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

    NCT03339258 · start 2018-04-15

    Registered record
    Registry ID
    NCT03339258
    Conditions
    Stress Disorders, Post-Traumatic
    Interventions
    Doxazosin Mesylate, Extended Release; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-04-15
    Completion
    2024-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic
    InterventionDoxazosin Mesylate, Extended Release; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Effects of Prazosin on the Attention-Enhancing Effects of Nicotine

    NCT03416569 · start 2018-03

    Registered record
    Registry ID
    NCT03416569
    Conditions
    no Condition, Basic Science
    Interventions
    Placebo; Nicotine; Prazosin; Nicotine + Prazosin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2018-03
    Completion
    2019-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Conditionno Condition, Basic Science
    InterventionPlacebo; Nicotine; Prazosin; Nicotine + Prazosin
    PhaseNot applicable
    Registry statusWithdrawn

  • Testing Doxazosin to Treat Stress Mechanisms in Alcoholism

    NCT02989493 · start 2017-04-12

    Registered record
    Registry ID
    NCT02989493
    Conditions
    Alcoholism
    Interventions
    Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-04-12
    Completion
    2020-03-13
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    InterventionDoxazosin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Prazosin for Post-Concussive Headaches

    NCT02965027 · start 2016-11-29

    Registered record
    Registry ID
    NCT02965027
    Conditions
    Post-Traumatic Headache
    Interventions
    Prazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11-29
    Completion
    2023-06-07
    Enrolment
    89

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Headache
    InterventionPrazosin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

    NCT02966340 · start 2016-11-01

    Registered record
    Registry ID
    NCT02966340
    Conditions
    Alcoholism
    Interventions
    Prazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2016-11-01
    Completion
    2018-03-12
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    InterventionPrazosin; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

    NCT02384369 · start 2016-06

    Registered record
    Registry ID
    NCT02384369
    Conditions
    Post-Traumatic Stress Disorders; Posttraumatic Stress Disorders; Stress Disorders, Post-Traumatic; Post-Traumatic Stress Disorders, Combat-related
    Interventions
    SNC-102 sustained release tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-06
    Completion
    2017-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorders; Posttraumatic Stress Disorders; Stress Disorders, Post-Traumatic; Post-Traumatic Stress Disorders, Combat-related
    InterventionSNC-102 sustained release tablet
    PhasePhase 2
    Registry statusWithdrawn